Crohn's Disease and Ulcerative Colitis Trials Available at the University of Chicago

Trial #1: Etrolizumab vs. Adalimumab (Humira) for Ulcerative Colitis

Summary: This study is evaluating how safe and effective etrolizumab is compared to adalimumab (Humira) and placebo for the treatment of moderate to severe ulcerative colitis. Participants must have not tried an anti-TNF therapy (e.g. Remicade, Humira or Cimzia).

Key Eligibility Criteria: You may be eligible to participate if you meet the following key criteria:
• Age 18 to 80 years
• Diagnosed with ulcerative colitis at least three months prior
• Moderately to severely active ulcerative colitis (i.e. not in remission)
• Naive to treatment with TNF inhibitor therapy
• Have not previously been treated with Entyvio (vedolizumab)

Location: University of Chicago Medicine, 5758 South Maryland Avenue, MC 9028, DCAM 0301, Chicago, IL 60637

Intestine
Stay informed about the latest information on Crohn's and colitis
Stay Informed

Sponsor: Genentech

Trial #2: Etrolizumab for Crohn's Disease

Summary: This study is evaluating how safe and effective etrolizumab is compared to placebo for the treatment of moderate to severe Crohn's disease.

Key Eligibility Criteria: You may be eligible to participate if you meet the following key criteria:
• Age 18 to 80 years
• Diagnosed with Crohn’s disease
• Moderately to severely active Crohn’s disease (i.e. not in remission)
• Have not previously been treated with Entyvio (vedolizumab)

Location: University of Chicago Medicine, 5758 South Maryland Avenue, MC 9028, DCAM 0301, Chicago, IL 60637

Sponsor: Genentech

Updated May 6, 2019

To see if you pre-qualify for a clinical trial, check here.

Support
Get the latest updates from Discover Therapies about your condition.